28247279 30105744 28164248 29056853 33658767 31933286 31660244 32692379 30201047 29405516 28074423 32931060 30003610 29488288 26597624 - Search Results

Year	Number of Results
2015	1
2016	1
2017	4
2018	5
2019	2
2020	2
2021	1
2022	0

1

Patient and Physician Perceptions of Drug Safety Information for Sleep Aids: A Qualitative Study.

Kesselheim AS, McGraw SA, Dejene SZ, Rausch P, Dal Pan GJ, Lappin BM, Zhou EH, Avorn J, Campbell EG. Kesselheim AS, et al. Drug Saf. 2017 Jun;40(6):531-542. doi: 10.1007/s40264-017-0516-3. Drug Saf. 2017. PMID: 28247279

2

Patient Understanding of the Neuropsychiatric Risks Associated with Branded Bupropion Hydrochloride Products Used for Smoking Cessation.

Ascher J, Stemhagen A, Stender M, Win B, Winter C. Ascher J, et al. Drugs Real World Outcomes. 2018 Sep;5(3):181-191. doi: 10.1007/s40801-018-0140-2. Drugs Real World Outcomes. 2018. PMID: 30105744 Free PMC article.

3

Medication Risk Communication in Rheumatology: Where Are We and Where Do We Go from Here?

Blalock SJ. Blalock SJ. Curr Rheumatol Rep. 2017 Feb;19(2):7. doi: 10.1007/s11926-017-0631-2. Curr Rheumatol Rep. 2017. PMID: 28164248 Review.

4

Evaluation of Risk-Minimization Activities for Cyproterone Acetate 2 mg/Ethinylestradiol 35 µg: A Cross-Sectional Physician Survey.

Davis KH, Asiimwe A, Zografos LJ, McSorley DJ, Andrews EB. Davis KH, et al. Pharmaceut Med. 2017;31(5):339-351. doi: 10.1007/s40290-017-0203-9. Epub 2017 Aug 28. Pharmaceut Med. 2017. PMID: 29056853 Free PMC article.

5

Patient Knowledge of Safe Use of ER/LA Opioid Analgesics Following Implementation of the Class-Wide REMS: A Survey Study.

Esposito DB, Desai VCA, Stephenson JJ, Cepeda MS, Lyons JG, Holick CN, Wedin GP, Lanes S; members of the REMS Program Companies Metrics Subteam. Esposito DB, et al. Patient Prefer Adherence. 2021 Feb 24;15:431-442. doi: 10.2147/PPA.S286935. eCollection 2021. Patient Prefer Adherence. 2021. PMID: 33658767 Free PMC article.

6

Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept in Europe: Evaluation of Risk-Minimization Measures.

Zografos LJ, Andrews E, Wolin DL, Calingaert B, Davenport EK, Hollis KA, Schmidt-Ott UM, Petraro P, Vassilev ZP. Zografos LJ, et al. Pharmaceut Med. 2019 Jun;33(3):219-233. doi: 10.1007/s40290-019-00279-y. Pharmaceut Med. 2019. PMID: 31933286

7

Advancing regulatory science and assessment of FDA REMS programs: A mixed-methods evaluation examining physician survey response.

Brewer SE, Campagna EJ, Morrato EH. Brewer SE, et al. J Clin Transl Sci. 2019 Sep 13;3(4):199-209. doi: 10.1017/cts.2019.400. eCollection 2019 Aug. J Clin Transl Sci. 2019. PMID: 31660244 Free PMC article.

8

Use of Risk Evaluation and Mitigation Strategies by the US Food and Drug Administration, 2008-2019.

Guadamuz JS, Qato DM, Alexander GC. Guadamuz JS, et al. JAMA. 2020 Jul 21;324(3):299-301. doi: 10.1001/jama.2020.6611. JAMA. 2020. PMID: 32692379 No abstract available.

9

Rational use of paracetamol among out-patients in a Bhutanese district hospital bordering India: a cross-sectional study.

Dorji T, Gyeltshen K, Pongpirul K. Dorji T, et al. BMC Res Notes. 2018 Sep 10;11(1):660. doi: 10.1186/s13104-018-3764-0. BMC Res Notes. 2018. PMID: 30201047 Free PMC article.

10

Assessment of Risk Evaluation and Mitigation Strategies (REMS) for varenicline (Chantix): A multistage patient survey.

Amend KL, Younus M, Petronis KR, Mo J, Seeger JD, Gately R, Gu X, Enger C. Amend KL, et al. Pharmacoepidemiol Drug Saf. 2018 Mar;27(3):253-262. doi: 10.1002/pds.4373. Epub 2018 Feb 6. Pharmacoepidemiol Drug Saf. 2018. PMID: 29405516

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results